Maintaining cognitive health is becoming increasingly important in the modern age as we navigate a world filled with distractions and stressors. Supplements that promote brain health, such as Divine ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Red 3 — also called FD&C Red No. 3, erythrosine, or E127 – has been widely used in food, cosmetics, and pharmaceuticals since its FDA approval in 1969. You’ve likely encountered Red 3 before.

The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery. Pain is registered in ...

Convenience: For individuals who do not regularly consume fish or plant-based omega-3 sources, supplements such as fish oil capsules offer an easy alternative to meet the daily recommended intake ...

Else Nutrition Holdings Inc (ELSE) reported a robust start to 2022 with significant revenue growth and improved profitability. The company, known for its plant-based, dairy-free nutrition products, ...

Additionally, choose a supplement that is made from sustainably sourced fish or plant-based ingredients. By considering these factors, you can choose the best omega 3 supplement for your child’s ...

Research has pursued the idea of omega-3 fatty acids ... these medications are FDA-approved for the treatment of Cushing's syndrome. When it comes to cortisol supplements and stress-coping ...

It was first approved by the FDA in 1907. However, concerns about its safety began to surface over recent decades. Studies in the 1980s showed that high doses of Red No. 3 could cause thyroid ...

Alia Shoaib is a freelance news reporter for Newsweek based between London ... conjunction with an oral medication. The FDA has now expanded its approval to include the standalone use of the ...

Spravato’s approval for standalone use is based on a study in which patients treated with the therapy showed a rapid and superior improvement in severity of depressive episodes, compared to placebo.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...